Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [November 2017]

Product Code:
596200931
Publication Date:
November 2017
Format:
PDF
Price:
£910

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Verzenio (abemaciclib; Eli Lilly) for HR+/HER2- BC; the European approval of Kisqali (ribociclib; Novartis) for HR+/HER2- BC; as well as Samsung Bioepis announcing the European approval of Ontruzant, a biosimilar version of Herceptin (trastuzumab), for the treatment of early BC, metastatic BC and metastatic gastric cancer.

Business Questions:

• How do KOLs view Verzenio’s approval?
• According to KOLs, how will Verzenio be prescribed?
• What are Kisqali’s advantages and disadvantages?
• How do KOLs view biosimilar trastuzumab and how is it expected to be used?
• What factors, if any, are likely to impact biosimilar trastuzumab uptake?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved